Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAMYWL)

Drug Name
BMY-27709 Drug Info
Synonyms
BMY-27709; AC1L2RSV; AC1Q3LRY; 99390-76-8; CHEMBL68649; Brl 20627; SCHEMBL15532024; 4-amino-5-chloro-2-hydroxy-n-[(2s,6r,9ar)-6-methyloctahydro-2h-quinolizin-2-yl]benzamide; 4-Amino-5-chloro-2-hydroxy-N-(octahydro-6-methyl-2H-quinolizin-2yl)benzamide; N-[(2S,6R,9aR)-6-methyl-2,3,4,6,7,8,9,9a-octahydro-1H-quinolizin-2-yl]-4-amino-5-chloro-2-hydroxy-benzamide; Benzamide, 4-amino-N-[(2S,6R,9aR)-octahydro-6-methyl-2H-quinolizin-2-yl]-5-chloro-2-hydroxy-
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
127317
CAS Number
CAS 99390-76-8
TTD Drug ID
DMAMYWL

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Influenza Hemagglutinin (Influ HA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Arbidol DMOQK8Z Virus infection 1A24-1D9Z Approved [2]
CR8020 DMQ47U6 Influenza virus infection 1E30-1E32 Phase 2 [3]
RG7745 DMK5PYS Infectious disease 1A00-CA43.1 Phase 2 [4]
VIS410 DM1G6ME Influenza A virus infection 1E30 Phase 2 [5]
ND-1.1 DMVQAEK Influenza virus infection 1E30-1E32 Phase 1 [6]
VGX-3400 DMGMEH7 Influenza A virus H5N1 infection 1E30 Phase 1 [7]
A/Anhui/05 DMGJ7A4 Influenza virus infection 1E30-1E32 Phase 1 [8]
VIR-2482 DM6LQIU Influenza A virus infection 1E30 Phase 1 [9]
Alpha-D-Mannose DMF5DLW Discovery agent N.A. Investigative [10]
PXVX-0103 DM2P0I4 Discovery agent N.A. Investigative [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Influenza Hemagglutinin (Influ HA) TTF4CAM HEMA_I34A1 Inhibitor [1]

References

1 Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17736-41.
2 Pharmacokinetic properties and bioequivalence of two formulations of arbidol: an open-label, single-dose, randomized-sequence, two-period crossover study in healthy Chinese male volunteers. Clin Ther. 2009 Apr;31(4):784-92.
3 Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin. J Virol. 2014 Dec;88(23):13580-92.
4 Clinical pipeline report, company report or official report of Roche.
5 Clinical pipeline report, company report or official report of Visterra.
6 An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models. Clin Vaccine Immunol. 2013 Jan;20(1):85-94.
7 Clinical pipeline report, company report or official report of Inovio Pharmaceuticals.
8 A Human Antibody Recognizing a Conserved Epitope of H5 Hemagglutinin Broadly Neutralizes Highly Pathogenic Avian Influenza H5N1 Viruses. J Virol. 2012 March; 86(6): 2978-2989.
9 Clinical pipeline report, company report or official report of Vir Biotechnology.
10 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
11 Company report (PaxVax)